Last reviewed · How we verify

NCT05842980: BIPROS

BIomarkers to Predict the Outcomes of Sepsis

Status unknown Last updated 6 May 2023
What this trial tests

trial testing sepsis in Sepsis in 1,000 participants. Status unknown.

Timeline
1 June 2020
Primary endpoint
1 June 2025
1 June 2025

Quick facts

Lead sponsorQilu Hospital of Shandong University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 June 2020
Primary completion1 June 2025
Estimated completion1 June 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Qilu Hospital of Shandong University

Who can join

Adults 18 to 85, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis is an organ dysfunction syndrome caused by the host's immune response to infection, and is one of the common critical illnesses. However, sepsis remains the main threat to global health. Due to the high heterogeneity, the diagnosis of sepsis is difficult, and it is particularly important to find biomarkers that can predict changes in the patient's condition and prognosis. The purpose of this study is to collect patient blood samples for testing and identify biomarkers related to the prognosis of sepsis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Biomarkers to guide sepsis management.
    Bourika V, Rekoumi EA, Giamarellos-Bourboulis EJ. · · 2025 · cited 5× · PMID 40685448 · DOI 10.1186/s13613-025-01524-1

Verify or expand the search:

Other trials of sepsis

Trials testing the same drug.

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05842980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing